A retrospective analysis of the efficacy between dasatinib and nilotinib for chronic myeloid leukemia

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-082
• By: WU, Chia-Hsuan (Chi-Mei Medical Center, Pharmacy, Tainan, China Taiwan)
• Co-author(s): Yu-Jou Lin Department of Pharmacy, Chi-Mei Medical Center, Tainan City, Taiwan, Province of China
  Chia-Hsuan Wu
  Hui-Chen Su
  
• Abstract:

  Background

  Chronic myeloid leukemia(CML) is a myeloproliferative disorder. Treatment decisions for CML include hematopoietic cell transplantation, tyrosine kinase inhibitors(TKIs) and other agents. TKIs including imatinib, dasatinib and nilotinib are often the first line therapy for newly diagnosed patients with CML.

  Purpose

  Imatinib was the first..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login